BLIS Technologies Limited (BLT.NZ)

NZD 0.02

(-11.76%)

Market Cap (In NZD)

19.18 Million

Revenue (In NZD)

11.52 Million

Net Income (In NZD)

646 Thousand

Avg. Volume

347.42 Thousand

Currency
NZD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.011-0.022
PE
-
EPS
-
Beta Value
0.418
ISIN
NZBLTE0002S8
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Scott Ogilvie Johnson B.Com., CMINSTD, M.B.A.
Employee Count
-
Website
https://www.blis.co.nz
Ipo Date
2001-07-29
Details
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of young children, as well as for improving immunity and bad breath; BLIS M18, an oral probiotic to support teeth, gums, and dental health; and BLIS Q24, a probiotic supplement to balance and restore the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.